Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
3/3 14:35
Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.64 per share a year ago. These figures are adjusted for non-recurring items....